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Edited by Ulrike KutayAbstract Caspase-2 exists as two main isoforms: the caspase-
2L long isoform, which is pro-apoptotic, and the caspase-2S
short isoform, which may be anti-apoptotic. Topoisomerase
inhibitors drive inclusion of exon 9, speciﬁc for Casp-2S mRNA,
and lower Casp-2S mRNA and protein. With cell lines engi-
neered to express various PKC isoforms, we demonstrate that
PKC zeta, but not PKCalpha, positively regulates Casp-2S
mRNA assembly triggered by topoisomerase inhibitors. In addi-
tion, exon 9 inclusion is lowered in mitosis but increased in the
G1/S phase. Hence, the control of caspase-2 exon 9 inclusion
by topoisomerase inhibitors depends on phosphorylation and/or
dephosphorylation events, and on the cell cycle phase.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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It is estimated that alternative pre-mRNA splicing events
occur at a frequency of at least 6–8 events per eukaryotic gene
[1,2]. The activity of splicing factors is controlled at various
levels, including subcellular localization [3] and phosphoryl-
ation [4–6] at serine and threonine residues. All gene families
are aﬀected by alternative splicing events, among which genes
involved in apoptosis control, such as caspase genes [7]. The
CASP-2 gene, encoding procaspases-2, is one such gene that
localizes to human chromosome 7, and encodes two main iso-
forms [8], the caspase-2L long isoform and the caspase-2S
short isoform (Fig. 1). The long isoform is the most abundant
and is now believed to be a major initiator caspase involved in
drug-induced apoptosis, whereas the short isoform is anti-
apoptotic when over-expressed [9]. These proteins originate
from translation of two partially overlapping mRNA species,
associated with two selective splicing events [10]. Caspase-2S
is derived from the speciﬁc inclusion of exon 9 into its mRNA,
which leads to the insertion of a premature translational stop
codon, and thus to a truncated protein. However, this protein*Corresponding author. Address: Inserm U613/EA948, Faculty of
Medicine, 22 Avenue Camille Desmoulins, 29238 Brest Cedex 3,
France. Fax: +33 298018322.
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doi:10.1016/j.febslet.2007.12.032has never been detected in cells or tissues, which is likely to be
related to the very poor stability of its mRNA that is subjected
to Nonsense-Mediated mRNA Decay [11].
We have shown that topoisomerases control Casp-2 pre-
mRNA splicing, as both topoisomerase I and II inhibitors trig-
ger inclusion of the alternative exon 9 into Casp-2S mRNA in
leukaemia cell lines with wt topoisomerase genes, but not in
mutant cells harbouring inactive forms of either enzyme
[12,13]. Importantly, the increase in Casp-2S pre-mRNA
occurs at the expense of Casp-2L mRNA and protein, which
are decreased [12]. The link between the activity of topoisome-
rases and pre-mRNA splicing has not been studied in details.
However, it has been shown that DNA topoisomerase I carries
a speciﬁc kinase activity that can inﬂuence mRNA splicing on
phosphorylation of SR proteins [5]. In addition, topoisomerase
II also has an indirect kinase activity within the recently
described toposome macromolecular complex [14,15].
PKC comprises a large number of serine/threonine kinases,
which are activated by many extracellular signals [16]. PKCs
play fundamental roles in the assembly and function of the
cytoskeleton [17,18], in the activation of transcription factors
[19,20], in diﬀerentiation processes [21], in the control of
drug-induced apoptosis of cancer cells [22], and in the cellular
cycle [23,24]. Twelve diﬀerent isoforms have been characterized
and are classiﬁed into three categories, based on their mode of
activation [25]. The group of classical PKCs (cPKCs) contains
the alpha, beta I, the splice variant beta II and gamma isoforms,
all of which depend on calcium, diacylglycerol (DAG) and
phosphatidylserine (PS) for activation. The new PKCs
(nPKCs) include the delta, epsilon, eta and theta isoforms,
are independent of calcium but require DAG and PS. The third
group of isoforms is that of the atypical PKCs (aPKCs), zeta,
lambda/iota, which activation requires only PS. PKC zeta has
been shown to play an important role in drug-dependent apop-
tosis, protecting the cells from apoptosis. Over-expression of
PKC zeta reduces apoptosis induced by various stimuli in sev-
eral cell lines [26,27]. On the contrary, kinase-defective PKC
zeta mutant sensitizes tumour cells to apoptosis induced by eto-
poside (the topoisomerase II inhibitor VP16) in vitro and
in vivo [22]. Upon induction of Casp-2 pre-mRNA splicing
by etoposide, we observed a reduction in procaspase-2L
[12,13]. Because PKC zeta reduces the ability of etoposide to
trigger apoptotic cell death, we wanted to determine whether
PKC zeta could control the eﬀect of topoisomerase inhibitors
on Casp-2 pre-mRNA splicing, upon increasing the ratio ofblished by Elsevier B.V. All rights reserved.
Fig. 1. Schematic representation of Casp-2 pre-mRNA and the two main transcripts (Casp-2L, Casp-2S). The boxes represent exons which are
separated by introns (lines). The transcriptional mRNA start sites, the translation initiation and termination codons are indicated. The position of
the primers used for RT-PCR assays are indicated by arrows.
S. Solier et al. / FEBS Letters 582 (2008) 372–378 373Casp-2S to Casp-2L mRNA, thereby reducing the amount of
procaspase-2L and thus potentially limiting apoptosis.
The results presented herein show that Casp-2S mRNA in-
duced by topoisomerase inhibitors is increased during the S
phase of the cell cycle. In addition, this splicing event is under
the control of PKC zeta, but not PKC alpha, in human leukae-
mia cells and in HeLa cells, which provides the ﬁrst evidence
that PKC zeta is involved in the control of pre-mRNA splicing
in human cells.2. Materials and methods
2.1. Cell lines and culture
The human leukaemia U-937 cell line (ATCC, Rockville, MD, USA)
was maintained in RPMI 1640 (BioWhittaker, Fontenay-sous-bois,
France) supplemented with 10% foetal calf serum (BioWhittaker).
The transfected derivatives of U-937 (see Section 3) were maintained
in RPMI 1640 supplemented with 10% foetal calf serum and antibiot-
ics. The HeLa cell line (ECACC, Salisbury, UK) was maintained in
EMEM (BioWhittaker) supplemented with 10% foetal calf serum
and 2 mM L-glutamine. The cells were cultivated in presence of 95%
air and 5% CO2. A mixed trypsin/EDTA solution (BioWhittaker) in
HBSS (BioWhittaker) was used to harvest adherent cells. Absence of
mycoplasma was determined with the ‘‘mycotech’’ kit (Gibco BRL,
Cergy-Pontoise, France). To ensure exponential growth at the start
of experiments, cells were suspended in fresh medium 24 h before each
treatment performed at the cell density of 106 ml1. The ﬁnal concen-
tration of DMSO, the solvent for most compounds, did not exceed
0.5% (v/v), a concentration that was not toxic to the cells.
2.2. Chemicals
All chemicals were from Sigma–Aldrich (Saint-Quentin Fallavier,
France), except Z-VAD-fmk (z-Val-Ala-DL-Asp-ﬂuoromethylketone,
R&D Systems, MN, USA).
2.3. Apoptosis determination
Cells (105) were washed in PBS (BioWhittaker), collected by centri-
fugation at 500 · g for 5 min and suspended in 500 ll Hoechst 33342-
containing PBS (ﬁnal concentration 2–10 lg/ml). After a 30 min
incubation in the dark at 37C, cells were centrifuged at 500 · g for
10 min, suspended in 20 ll PBS for analysis of nuclear fragmentation
by ﬂuorescence microscopy.
2.4. RT-PCR analysis
Cells were washed in PBS and RNA was extracted with the ‘‘Nucle-
ospin RNA II’’ kit (Macherey-Nagel, Hoerd, France). The ‘‘OneStep
RT-PCR’’ kit (QIAGEN, Courtaboeuf, France) was used according
the manufacturers instructions. The initial PCR step was activated
by heating for 15 min at 95 C prior to PCR (1 min denaturation at
94 C, 1 min annealing at 60 C, 1 min extension at 72 C, 29 or 32 cy-
cles) using a GeneAmp PCR System 2400 (Perkin–Elmer Instruments,
Les Ulis, France). The PCR products were separated on agarose gels,stained with ethidium bromide and ﬂuorescence was detected by video
camera imaging using the Photomat software (Microvision Instru-
ments, Evry, France) and the Gel Doc software (Bio-Rad, Marnes
La Coquette, France). Quantitative data were obtained by densitome-
try analysis of gel scans (ImageQuant, Bio-Rad). The PCR primers (5 0
to 3 0) were as follows:
5 0hb2, CTCACGTCATCCAGCAGAGA;
3 0hb2, TCTTTTTCAGTGGGGGTGAA;
5 0hICH-1, GTTACCTGCACACCGAGTCACG;
3 0hICH-1, GCGTGGTTCTTTCCATCTTGTTGGTCA;
OLKPCA-s, ATGGCTGACGTTTTCCCGGG;
OLKPCA-as, TCATACTGCACTCTGTAAGATGG;
OLPRKCZ-s, ATGCCCAGCAGGACCGGCCC;
OLPRKCZ-as, TCATCGTCTGGGGTCAGCTG.
2.5. Engineering PKC expression plasmids
The full length coding sequences of PKC alpha and PKC zeta were
isolated by RT-PCR from HeLa cell mRNA and inserted into the
pcDNA3.1 (Invitrogen, Cergy Pontoise, France) plasmid. PKC alpha:
PRKCA, NM_002737, was ampliﬁed using OLKPCA-s and OLKP-
CA-as. PKC zeta: PRKCZ, NM_002744, was ampliﬁed using
OLPRKCZ-s and OLPRKCZ-as.
2.6. Flow cytometry analysis
A total of 3 · 106 cells were washed in 10 ml of PBS, centrifuged and
suspended in 500 ll of PBS, ﬁxed with 1.5 ml of ice-cold ethanol, and
incubated overnight at 4C. The ﬁxed cells were harvested by centrifu-
gation, washed, and suspended in 1 ml of PBS, 10 ll of RNase (10 mg/
ml), 1 ll of propidium iodide (25 mg/ml) and incubated in the dark at
37 C for 1 h. Cells were then washed, suspended in PBS and 2 ll of
propidium iodide were added, prior to DNA content determination
by FACS analysis (FACSCalibur, Becton Dickinson).3. Results
3.1. PKC zeta controls Casp-2 alternative splicing triggered by
topoisomerase inhibitors
In order to analyze the putative role of PKC zeta in the con-
trol of Casp-2 exon 9 inclusion, we utilized various derivatives
of the U-937 leukaemia cells harbouring distinct PKC isoforms
(PKC zeta [22]; PKC alpha [28]). Cell lines stably transfected
with either an insertless vector (P1) or a kinase-modiﬁed
PKC zeta-containing vector (Z4, mutHA) cells were used. P1
cells were engineered to contain an empty vector, whereas Z4
cells and mutHA cells (expressing PKC zeta isoforms derived
from frog and human, respectively) over-expressed mutated
PKC zeta isoforms devoid of kinase activity. Etoposide has
been shown by one of us (AB) to activate PKC zeta in P1 cells,
but not in the cell lines over-expressing a PKC zeta mutant
form, despite presence of the endogenous wt PKC zeta [22].
Therefore, these cells, which contain a kinase-defective domi-
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PKC zeta-dependent kinase activity. RT-PCR experiments
were conducted to determine directly the levels of exon 9-con-
taining and exon 9-lacking Casp-2 mRNA species, as previ-
ously described (Fig. 1; [12]). In Z4 cells and mutHA cells,
the stimulatory eﬀect of VP16 or camptothecin on Casp-2
alternative splicing was reduced (Fig. 2A and B). However,
no change was observed with U-937 cells expressing a
kinase-modiﬁed (dominant negative (DNT3), or over-
expressed (PKCalphawtT1)) PKC alpha isoform (Fig. 2C).
The activity of the PKC alpha constructs has been character-
ized by Baier-Bitterlich et al. [28], and these appeared to be
functional in the stably transfected cells used here. Firstly,
Fig. 2D shows cell pictures that were indicative of polyploidy
in PKC alpha DN-overexpressing U-937 cells. Secondly, the
results of apoptosis determination have shown that U-937 cells
over-expressing wt PKC alpha (wtT1) were more sensitive than
U-937 cells to VP16-induced apoptosis (45% apoptosis in wtT1
cells vs. 26% apoptosis in U-937 following treatment by 10 lM
VP16 for 6 h, P < 0.004) (data not shown). These results were
conﬁrmed in kinetics experiments which showed that splicing
induction was readily observed after 20 min, and peaked after
40 min of treatment for U-937 control cells but not for PKC
zeta-modiﬁed cells, whereas PKC alpha-modiﬁed cells behaved
as control cells (data not shown). All these results pointed to aD
PKC zeta
A
VP16
2S
2L
β2
P1 Z4 mutHA
+++
1.
23
2.
17
1.
14
1.
61
1.
16 1.
26(2S/2L) / β2
1 2 3 4 5 6
B
camp
(2S/2L)
PKC alpha
C
β2
2S
2L
1.
30
1.
31
1.
24
1.
80
1.
92
1.
83(2S/2L) / β2
1 2 3 4 5 6
VP16 + + +
Fig. 2. Eﬀect of topoisomerase inhibitors on Casp-2S exon 9 inclusion in U
RT-PCR using 5 0hICH-1 and 3 0hICH-1 primers. Control cells received veh
control. (A) Eﬀect of VP16 on exon 9 inclusion in U-937 cells transfected wi
zeta cDNA-expressing vector (Z4, mutHA). Lanes 1, 2: P1; lanes 3, 4: Z4; la
DMSO, 4 h). (B) Eﬀect of camptothecin or VP16 on exon 9 inclusion in U-
negative mutated PKC zeta cDNA-expressing vector (Z4). Lanes 1–6: P1; la
(10 lM in DMSO, 4 h); lanes 5, 6, 11, 12: VP16 (50 lM, 4 h). C. Eﬀect of top
cells transfected with a modiﬁed PKC alpha-encoding vector (PKC alpha ove
2, 5: wtT1; lanes 3, 6: DNT3; lanes 1, 2, 3: control; lanes 4, 5, 6: VP16 (50
independent experiments with similar results. D. Evidence for morphologica
single nuclei, DNT3 cells show ﬁgures indicative of polyploidy (same magniﬁ
represent the ratios of exon 9-containing to exon 9 lacking PCR products, sta
The standard error for the replicate experiments was 60.11. All the numberspeciﬁc role of PKC zeta in the control of Casp-2 exon 9 inclu-
sion in human leukaemia cells treated with topoisomerase I or
II inhibitors. To further analyse the role of PKC zeta, we engi-
neered PKC alpha and PKC zeta expression plasmids, and
transiently transfected these into HeLa cells. The results show
that over-expression of wt PKC zeta, but not wt PKC alpha
(Fig. 3, compare lanes 7 and 8 to lanes 5 and 6), increased
the ratio of exon 9-containing to exon 9-lacking Casp-2
mRNA in response to camptothecin treatment. Taken
together, these results strongly suggest that PKC zeta plays a
positive role in the control of Casp-2 pre-mRNA splicing in
response to DNA topoisomerase inhibitors.
3.2. Stopping cells in mitosis, but not in G1/S, decreases the
eﬀect of topoisomerase inhibitors on Casp-2 mRNA
alternative splicing
Topoisomerase inhibitors are most active during DNA syn-
thesis, i.e. when DNA relaxation–religation is more required.
In addition, activation of PKC by phorbol 12-myristate 13-
acetate (PMA) inhibits the cell cycle at the G1/S and G2/M
transitions upon upregulation of p21 [23]. In order to see
whether Casp-2 mRNA alternative splicing could vary
throughout the cell cycle, we ﬁrst arrested U-937 cells in the
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Fig. 3. Eﬀect of camptothecin on Casp-2S exon 9 inclusion in transiently transfected HeLa cells. PKC alpha and PKC zeta expression plasmids were
transfected into HeLa cells, and 4 lM camptothecin was used 24 h later for 4 h. b2 microglobulin (b2) mRNA was used as a standardizing control. A.
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cells, by ﬂow cytometry analysis. Treatment of cells with noco-
dazole (0.13 lM) for 24 h resulted in an enrichment of cells in
the G2/M phase to approximately 71%, compared with 12%
for exponentially growing cells (Fig. 4A). In G2/M, the eﬀect
of VP16 or camptothecin (data not shown) on Casp-2 mRNA
alternative splicing was lower compared to asynchronous cells
(Fig. 4B). Next, U-937 cells were synchronized in G1/S by
treatment with thymidine (double block). This treatment
resulted in an enrichment of cells in G1/S phase to approxi-
mately 68%, compared with 20% in exponentially growing cells
(Fig. 4C). In these cells, the eﬀect of VP16 or camptothecin on
Casp-2 exon 9 inclusion was higher compared to asynchronous
cells (Fig. 4D). Identical results were obtained with cells carry-
ing a PKC zeta mutation (Fig. 5A and B), or in HeLa cells
(data not shown). In Z4 cells, we observed that treatment by
nocodazole also induced a strong apoptosis (33%, Fig. 5A).
Hence, to eliminate a possible interference with apoptosis,
we treated Z4 cells with or without VP16 and Z-VAD-fmk, a
broad-spectrum caspase inhibitor and a strong blocker of cas-
pase-dependent apoptosis. The results show that the eﬀect on
splicing was independent of the level of ongoing apoptosis,
which was strongly suppressed in presence of Z-VAD-fmk. Ta-
ken together, these results indicate that the activity of PKC
zeta in splicing control is independent of the cell cycle phase,
but the splicing inducing ability of topoisomerase inhibitors
is stimulated in cells that replicate DNA more actively.4. Discussion
The present results show that the stimulatory eﬀect of topo-
isomerase inhibitors on Casp-2 alternative mRNA splicing de-
pends, in part, on the activity of PKC zeta, whereas PKC
alpha plays no role in this control. To our knowledge, this is
the ﬁrst report that identiﬁes the PKC zeta isoform as an inter-
mediate in pre-mRNA splicing. Several hypotheses could be
proposed to account for this eﬀect. For example, traﬃcking
and/or subcellular localization of splicing proteins could be
important as PKC zeta has been shown to phosphorylate het-
erogeneous nuclear ribonucleoprotein (hnRNP) A1, which
controls its nucleo-cytoplasmic shuttling, and hence RNA
maturation steps [3]. This activity of PKC zeta could thus con-
trol the stimulation of Casp-2S exon 9 inclusion obtained in
response to hnRNP A1 overexpression [29]. Accordingly, the
level of hnRNP A1 phosphorylation would be lower in cells
harbouring a mutant form of PKC zeta, thereby leading to a
drop in the splicing stimulation brought about by topoisomer-
ase inhibitors, which is what we observed here. In addition, SR
proteins, which are mandatory for splicing reactions, are phos-
phorylated by various protein kinases [30]. Interestingly,
although PKC alpha had no role in the control of Casp-2 exon
9 inclusion level in the present study, it has been shown to
interact, in the nucleus, with PTB-associated splicing factor
(PSF), p68 RNA helicase, and the hnRNP A3 and hnRNP
L, although only PSF appeared to be weakly phosphorylated
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376 S. Solier et al. / FEBS Letters 582 (2008) 372–378by this PKC isoform [31]. In addition, it was shown that PMA,
(Phorbol 12-Myristate 13-Acetate) a PKC activator, could
stimulate SRp30 protein phosphorylation and the aggregation
of nuclear speckles, the reservoirs of SR proteins [32]. PKC
zeta over-expression has been shown to result in phosphoryla-
tion of topoisomerase II beta and in a decrease of its catalytic
activity [33]. Such a phosphorylation event could thus modify
the role of topoisomerase II in pre-mRNA splicing, and may
partly explain our results.
Strikingly, the level of Casp-2 splicing (in favour of Casp-2S)
is higher during the S phase, when topoisomerase inhibitors ex-
ert stronger DNA damaging eﬀects [34]. Therefore, our results
indicate that Casp-2 exon 9 inclusion may be more eﬃcient
when DNA topoisomerases complexes are stabilized as a result
of inhibitor interaction. Because transcription and splicing are
in coupling [35–37], our results could be well explained by the
kinetics model of Kornblihtt [38]. Accordingly, a slow RNA
polymerase II (which is mimicked by the stalling of RNA poly-
merase II by stabilised TOPO I-DNA complexes [39], and pos-
sibly TOPO II-DNA complexes) may allow the spliceosome to
recognise, and thus utilise more eﬃciently weaker splicing sites
to include, in our case, Casp-2 exon 9 better. In addition, DNA
topoisomerase I relaxing activity is stimulated upon interac-
tion with the late splicing factor PSF/p54 [40]. Inversely,
DNA topoisomerase I activity is shifted from relaxation tokinasing by interaction with the RNA splicing factor ASF/
SF2 [41]. Such a functional link between topoisomerase activ-
ity and splicing factors could thus, at least in part, account for
our observations. In addition, our results, although they do
not argue in favour of a speciﬁc role of PKC zeta isoform in
splicing control during selective cell cycle phases, agree with
the general notion that pre-mRNA splicing is inhibited during
mitosis, and active during DNA synthesis [42].
In our previous studies, we demonstrated that, whereas sev-
eral topoisomerase I inhibitors could trigger Casp-2 exon 9
inclusion, indolocarbazole derivatives were inactive [12]. Strik-
ingly, it has been shown that some indolocarbazole com-
pounds are eﬃcient inhibitors of PKC zeta [25,43]. Taken
together, these data suggest that, upon inhibition of PKC zeta,
topoisomerase-dependent pre-mRNA splicing is signiﬁcantly
hampered. The precise mechanism of action of PKC zeta in
this control, including the involvement of putative SR protein
targets and the analysis of their subcellular localization, will
require further investigations. Already, it should be conceiv-
able to try to modulate pre-mRNA splicing by the selective
inhibition of this speciﬁc PKC isoform [44]. In the case of
Casp-2 mRNA, such an eﬀect would be expected to limit
the decrease of the long, pro-apoptotic isoform observed in
response to topoisomerase inhibitors [12], and to allow cancer
cell apoptosis induction to proceed optimally.
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DMSO) was added with nocodazole. Lanes 1–4: asynchronous Z4
cells; lanes 5–8: Z4 cells stopped in mitosis. Lanes 1, 5: control; lanes 2,
6: VP16 (50 lM, 4 h); lanes 3, 7: Z-VAD-fmk (100 lM); lanes 4, 8:
VP16 (50 lM, 4 h) + Z-VAD-fmk. (B) Eﬀect of VP16 on exon 9
inclusion in Z4 cells synchronized in G1/S. Cells were treated as
indicated. Lanes 1, 2: asynchronous Z4 cells; lanes 3, 4: Z4 cells
synchronized in G1/S (73% of the cells are in the DNA synthesis
phase). Lanes 1, 3: control; lanes 2, 4: VP16 (50 lM, 4 h). *See the
legend to Fig. 2.
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